MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock...
$358,986
(-96.27%↓ Y/Y)
Net cash provided by
financing activities
$345,033
(-95.67%↓ Y/Y)
Canceled cashflow
$13,953
Net (decrease)
increase in cash and cash...
-$756,415
(-111.50%↓ Y/Y)
Canceled cashflow
$345,033
Accounts receivable
-$798,418
(-352.01%↓ Y/Y)
Accrued expenses,
operating leases and other...
$361,412
(201.26%↑ Y/Y)
Stock-based compensation
$352,777
(-61.06%↓ Y/Y)
Amortization and
depreciation
$47,002
(-76.18%↓ Y/Y)
Non-cash lease expense
$30,024
(-63.91%↓ Y/Y)
Valuation adjustments for
excess or obsolete...
$1,000
(-86.67%↓ Y/Y)
Issuance costs related to
equity financings
-$10,777
Share repurchases for
the payment of...
$3,176
(-97.39%↓ Y/Y)
Net cash used in
operating activities
-$1,081,789
(17.52%↑ Y/Y)
Canceled cashflow
$1,590,633
Net cash used in
investing activities
-$19,659
(72.36%↑ Y/Y)
Net loss
-$2,006,331
(-1.02%↓ Y/Y)
Fair value change in
warrant liability
-$405,702
(63.10%↑ Y/Y)
Inventory
$191,839
(126.28%↑ Y/Y)
Prepaid expenses
$35,224
(108.40%↑ Y/Y)
Accounts payable
-$33,326
(88.39%↑ Y/Y)
Purchase of property and
equipment
$19,659
(-72.36%↓ Y/Y)
Back
Back
Cash Flow
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
source: myfinsight.com